Team Stéphane DALLE – Eric RENARD
Innovative therapeutics for diabetes
Project Inflammatory and metabolic stress of the pancreatic beta cell
PRINCIPAL INVESTIGATOR
IGF staff involved
Eric RENARD
PUPH CHU Université Montpellier
None of the antidiabetic drugs currently available promotes the maintenance of a functional beta-cell mass. This research group identifies molecules, signaling networks and mechanisms, targets of pharmacological interest to protect beta cells from dysfunction and destruction by apoptotic death when exposed to pro-inflammatory cytokines and/or metabolic stress such as chronic hyperglycemia, that could pave the way for the development of innovative therapies for type 1 and type 2 diabetes.
Insulin secretion and survival/death of beta cells, signaling networks and mechanisms, pharmacological targets, are studied in beta cell lines, pancreatic islets (mice and humans), and in vivo preclinical models of diabetic animals.
More specifically, the current projects are:
- Identification of pathogenic signaling networks and mediators common to dysfunction and death of beta cells exposed to inflammation and chronic hyperglycemia: Focus and interest on MAP3K8 kinase to prevent beta cell failure and to reduce diabetes progression.
- Identification and characterization of new molecules with antidiabetic effects.
Main publications
• Dalle S., et al. (mars, 2024) Cells, in press
• Dalle S., et al. (mars, 2024) Int J Mol Sci, in press.
• Dalle S., et al. (2023) Front Endocrinol, 15, 1076343.
• Tenenbaum M., et al. (2021) Cell Mol Life Sci, 78, 287.
• Varin EM., et al. (2016) Cell Death Dis, 7, e2065.
Funding
• 2019-2021: Phd Cifre Contract MedBioMed, Coordinator
• 2013-2018: Industrial Contract CisBio Assays, Coordinator
Collaborations
• Amar Abderrahmani (IEMN, Lille)
• Jean François Tanti (C3M, Nice)
• Christophe Broca, Julia Sabatier (LTCD Plateforme isolement îlots humains, Montpellier)
Alumni
• Morgane Delobel (Thèse)
